4项3期试验中SARS-CoV-2病毒载量与COVID-19疫苗接种之间的关联
Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials.
作者信息
Janes Holly, Fisher Leigh H, Kee Jia Jin, Parameswaran Lalitha, Goepfert Paul A, Falsey Ann R, Ludwig James, Magaret Craig A, Gilbert Peter B, Kublin James G, Rouphael Nadine, Sobieszczyk Magdalena E, El Sahly Hana M, Baden Lindsey R, Grinsztejn Beatriz, Walsh Stephen R, Gray Glenda E, Kotloff Karen L, Gay Cynthia L, Greninger Alexander L, Tapia Milagritos D, Hammershaimb E Adrianne, Priddy Frances H, Green Justin A, Struyf Frank, Dunkle Lisa, Neuzil Kathleen M, Corey Lawrence, Huang Yunda
机构信息
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
New York University Langone Vaccine Center, New York University Grossman School of Medicine, New York, New York, USA.
出版信息
J Infect Dis. 2024 Dec 16;230(6):1384-1389. doi: 10.1093/infdis/jiae400.
Coronavirus disease 2019 (COVID-19) vaccines reduce severe disease and mortality and may lessen transmission, measured by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load (VL). Evaluating vaccine associations in VL at COVID-19 diagnosis in 4 phase 3 randomized, placebo-controlled vaccine trials, July 2020 to July 2021, VL reductions were 2.78 log10 copies/mL (95% confidence interval [CI], 1.38-4.18; n = 60 placebo, 11 vaccine) and 2.12 log10 copies/mL (95% CI, 1.44-2.80; n = 594 placebo, 36 vaccine) for NVX-CoV2373 and mRNA-1273, respectively. Associations were not significant for AZD1222 (0.59 log10 copies/mL; 95% CI, -.19 to 1.36; n = 90 placebo, 78 vaccine) or Ad26.COV2.S (0.23 log10 copies/mL; 95% CI, -.01 to .47; n = 916 placebo, 424 vaccine). Thus, vaccines potentially decreased transmission when ancestral SARS-CoV-2 predominated. Clinical Trials Registration. NCT04470427, NCT04505722, NCT04516746, NCT04611802.
2019冠状病毒病（COVID-19）疫苗可降低重症和死亡率，并可能减少传播，传播情况通过严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒载量（VL）来衡量。在2020年7月至2021年7月进行的4项3期随机、安慰剂对照疫苗试验中，评估COVID-19诊断时疫苗与病毒载量的关联，NVX-CoV2373和mRNA-1273的病毒载量降低分别为2.78 log10拷贝/毫升（95%置信区间[CI]，1.38 - 4.18；n = 60例安慰剂，11例疫苗）和2.12 log10拷贝/毫升（95% CI，1.44 - 2.80；n = 594例安慰剂，36例疫苗）。AZD1222（0.59 log10拷贝/毫升；95% CI，-0.19至1.36；n = 90例安慰剂，78例疫苗）或Ad26.COV2.S（0.23 log10拷贝/毫升；95% CI，-0.01至0.47；n = 916例安慰剂，424例疫苗）的关联不显著。因此，当原始SARS-CoV-2占主导时，疫苗可能降低了传播。临床试验注册编号：NCT04470427、NCT04505722、NCT04516746、NCT046！1802。 （注：原文中“NCT04611802”中的感叹号可能有误，这里按原文翻译）
Zotero 插件